Holen Sie sich die Stockscreener-App
1.9973
5.65%
0.1373
Schlusskurs vom Vortag:
$1.86
Offen:
$1.86
24-Stunden-Volumen:
137.74K
Relative Volume:
0.61
Marktkapitalisierung:
$17.93M
Einnahmen:
$170.00K
Nettoeinkommen (Verlust:
$-16.35M
KGV:
-1.0735
EPS:
-1.8605
Netto-Cashflow:
$-13.66M
1W Leistung:
+25.16%
1M Leistung:
+85.38%
6M Leistung:
-61.01%
1J Leistung:
-10.68%
1-Tages-Spanne:
$1.73
$1.9947
1-Wochen-Bereich:
$1.45
$1.99
52-Wochen-Spanne:
$0.9875
$5.07
Lisata Therapeutics Inc Stock (LSTA) Company Profile
Firmenname
Lisata Therapeutics Inc
Sektor
Branche
Telefon
908-229-2590
Adresse
110 ALLEN ROAD, BASKING RIDGE
Compare LSTA vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LSTA
Lisata Therapeutics Inc
|
1.99 | 16.76M | 170.00K | -16.35M | -13.66M | -1.8605 |
VRTX
Vertex Pharmaceuticals Inc
|
520.63 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.10 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,006.31 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.53 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.53 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lisata Therapeutics Inc Aktie (LSTA) Neueste Nachrichten
3 Promising Penny Stocks With At Least $10M Market Cap - Sahm
Single investor holds 5% slice of Lisata Therapeutics (LSTA) - Stock Titan
Enterprise value to EBITDA forward of Lisata Therapeutics, Inc. – NASDAQ:LSTA - TradingView
Lisata Therapeutics Inc. (NASDAQ: LSTA) Share Price, LSTA Stock News, LSTA Share Price & Updates - kalkine.ca
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Lisata (LSTA) Trading Levels Update: Climbs 6.48% to $1.15 in the Latest Session; Technical Focus: $1.09 and $1.21 Define the Nearby Reference LevelsHull Moving Average - vinanet.vn
Enterprise value to EBITDA forward of Lisata Therapeutics, Inc. – FWB:8NE - TradingView
Lisata Therapeutics (LSTA) Drops 4.24% to $1.13, Approaching Critical SupportBlue Chip Entry Points - Vinanet
Enterprise value to EBITDA forward of Lisata Therapeutics, Inc. – SWB:8NE - TradingView
Enterprise value to EBIT forward of Lisata Therapeutics, Inc. – NASDAQ:LSTA - TradingView
Lisata Therapeutics (8NE) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Lisata Therapeutics (LSTA) Slips 0.93% as Shares Hover Near Key Support at $1.02Money Flow - vinanet.vn
LISATA THERAPEUTICS, INC. 2026: Revenue $0 EPS ($0.32) — 10-Q Summary - TradingView
Lisata Therapeutics Announces Major Workforce Reduction and Retrenchment - The Globe and Mail
Lisata Therapeutics sues Kuva Labs, cuts 72% of workforce By Investing.com - Investing.com India
Lisata Therapeutics sues Kuva Labs, cuts 72% of workforce - Investing.com
Lisata Therapeutics, Inc. Continues to Evaluate Strategic Alternatives to Enhance Stockholder Value - marketscreener.com
Lisata Therapeutics (LSTA) Pursues Legal Action After Merger Ter - GuruFocus
Lisata Therapeutics, Inc. (LSTA) Files 8-K Announcing Retention Bonus Agreement With James Nisco - Minichart
Lisata Therapeutics Files Suit Against Kuva Labs, Reviews Strategic Alternatives and Cuts Workforce to Preserve Cash - Quiver Quantitative
Lisata Therapeutics, Inc. Implements a Reduction in Force, Eliminating Approximately 72% of Full-Time Employees - marketscreener.com
Lisata Therapeutics terminates Dr. Kristen K. Buck as EVP R&D & CMO; James Nisco awarded $200,000 retention bonus - TradingView
Lisata Therapeutics moves forward with legal action following Kuva merger termination - Proactive financial news
Lisata Therapeutics sues Kuva Labs after merger deal ends, cuts workforce by 72% to focus on strategy. - Pluang
CNSY Stock Price and Chart — NASDAQ:CNSY - TradingView
Lisata Therapeutics (LSTA) Drops 3.9% to $0.99 as Biotech Stock Presses Key SupportOrder Block - dars.gov.et
LSTA Q3 2025 Earnings: Narrower-than-Expected Loss Offers Modest Encouragement Despite Share DipEPS Surprise History - vinanet.vn
Lisata Therapeutics, Inc. Revenue Breakdown – NASDAQ:LSTA - TradingView
Kuva Labs (LSTA) ends Lisata cash-and-CVR tender offer after financing shortfall - Stock Titan
Lisata Therapeutics Inc (LSTA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Lisata Therapeutics Inc (LSTA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lisata Therapeutics (LSTA) Terminates Merger Agreement with Kuva Labs Amid Financing Issues - GuruFocus
LSTA|Lisata Therapeutics Inc|Price:1.470|Chg%:-0.200 - TradingKey
Lisata Therapeutics Inc (LSTA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lisata Therapeutics Inc (LSTA) Cash Flow - TradingKey
Lisata Therapeutics Inc (LSTA) Institutional Confidence - TradingKey
TradingKey - TradingKey
Lisata Therapeutics (LSTA) Plunges 21%: Key Levels to WatchZero Gamma Level - po-news-eg.net
Lisata Therapeutics, Inc. Revenue Breakdown – LS:A3DWGC - TradingView
Lisata Therapeutics Shares Fall After Terminating Kuva Labs Deal - Moomoo
Lisata Therapeutics Terminates Merger Agreement With Kuva Labs On July 24, Says SEC Filing - TradingView
Lisata Therapeutics Ends Kuva Merger, Starts Strategic Review - TipRanks
Lisata Therapeutics Stock Falls After Hours: Here's Why - webull.com
Lisata Therapeutics (LSTA) says Kuva tender meets conditions but financing not yet secured - Stock Titan
Kuva Labs, Inc. completed the acquisition of Lisata Therapeutics, Inc.. - marketscreener.com
Lisata Therapeutics (LSTA) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Enterprise value to EBIT forward of Lisata Therapeutics, Inc. – LSE:0HS8 - TradingView
Lisata Therapeutics Extends Merger Timeline with Kuva Labs - The Globe and Mail
Lisata Therapeutics Amends Merger Agreement with Kuva Labs—Key Details from Latest 8-K Filing - Minichart
Enterprise value to EBITDA forward of Lisata Therapeutics, Inc. – LSE:0HS8 - TradingView
Lisata Therapeutics, Kuva Labs Amend Merger Agreement to Extend Outside Date to July 21 - TradingView
Finanzdaten der Lisata Therapeutics Inc-Aktie (LSTA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.29%
4.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):